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We have recently demonstrated for the first time that inter-retroviral membrane fusion, i.e., membrane fusion between
individual retroviral particle populations with incorporated HIV-1 Env and cellular receptors, respectively, can occur (Sparacio
et al. 2000, Virology 271: 248–252). We have extended these analyses here and confirmed that fusion between particles can
occur in the extracellular medium independent of any cellular membranes and that luciferase transduction, mediated by the
fused structures, is independent of significant potential contribution by contaminating membrane vesicles. We have
additionally analyzed whether membrane fusion between HIV-like particles can be mediated by amphotropic murine leukemia
virus (MuLV) glycoprotein and its respective cellular receptor, PiT-2. We demonstrate that PiT-2 can be incorporated into
HIV-like particles and can fuse with MuLV-Env-carrying particles. This occurs only in the situation in which the incorporated
MuLV-Env protein has been activated to fusion activity by HIV protease-mediated removal of the C-terminal R-peptide and
is completely inhibited when the respective particles are generated in the presence of the HIV protease inhibitor, Saquinavir.
© 2002 Elsevier Science (USA)INTRODUCTION
We have recently demonstrated that different popula-
tions of retroviral particles carrying the viral and cellular
receptors of membrane viruses, respectively, are able to
specifically fuse with each other (Sparacio et al., 2000). In
addition to possible implications for in vivo infections
(Sparacio et al., 2000), this phenomenon may have prac-
tical applications, e.g., for the development of a fusion-
competent vaccine in analogy to the concept described
by LaCasse et al. (1999). In the experimental procedure
described in our previous report, HIV particles, lacking
viral glycoprotein but with incorporated CD4 and CXCR-4
and encoding a transducible luciferase marker gene
(designated target particles), were incubated with parti-
cles lacking a marker gene, but with incorporated HIV-
Env or HIV-Env plus VSV-G (designated fusion particles).
Subsequently the mixed preparations (but not several
negative controls) were able to transduce luciferase ac-
tivity to target cells. Infectivity of the fused structures
could be mediated either by HIV-Env (into CD4/corecep-
tor-expressing cells) or by VSV-G (into 293T cells). De-
spite extensive controls, a question which remained un-
answered in that report was whether inter-retroviral
membrane fusion took place in suspension completely305independent of cellular membranes. An alternative ex-
planation considered the possibility that preformed com-
plexes between the respective particles may initially fuse
with the target cell membrane and that, subsequently,
fusion with the target particle membrane would go to
completion (see Note Added in Proof in Sparacio et al.
(2000)). A further unanswered question concerned the
possibility that membrane vesicles, which may be gen-
erated in increased amounts on overexpression of sur-
face glycoproteins (e.g., Mack et al., 2000; Rolls et al.,
1994), could be contributing to the luciferase transduc-
tion observed. In this report, we have addressed these
questions and developed strategies which have allowed
us to establish that inter-retroviral fusion does occur
outside the cell and is largely independent of membrane
vesicles.
HIV and other retroviruses can be efficiently pseudo-
typed not only by several different viral glycoproteins but
also by several different cellular receptor glycoproteins.
Thus, for example, in addition to the HIV cellular recep-
tors, the cellular receptors for Rous sarcoma virus (Tva)
and ecotropic murine leukaemia virus (MCAT-1) can also
be incorporated into Env-defective retroviral particles
and mediate infectivity of cells carrying the respective
viral glycoprotein (Balliet and Bates, 1998). We thus
wished to extend our analyses of inter-retroviral fusion toKey Words: inter-retroviral fusion; HIV glycoprotein; CD4
transduction.
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Env) and its cellular receptor, PiT-2 (Miller et al., 1994;
van Zeijl et al., 1994). PiT-2 is a sodium-dependent phos-
phate transporter protein, which recently has been de-
scribed to exhibit a membrane topology with 12 trans-
membrane domains (Salaun et al., 2001). In the case of
MuLV-Env, membrane fusion activity is inhibited by the
presence of a sequence at the cytoplasmic C-terminus of
the transmembrane glycoprotein (the R-peptide). MuLV-
Env fusion competence is activated by proteolytic re-
moval of the R-peptide by the MuLV protease, a function
which can also be carried out by the HIV protease (Ki-
ernan and Freed, 1998). Thus, since conversion of MuLV-
Env to fusion competence is a late event occurring within
assembling or released particles in which viral protease
is activated subsequent to Gag-Pol multimerization, it is
unlikely that MuLV-Env molecules, potentially present in
contaminating cellular membrane vesicles, would be fu-
sion-competent. This makes this system particularly wor-
thy of investigation since potential inter-retroviral fusion
should be independent of contribution by fusable mem-
brane vesicles.
RESULTS AND DISCUSSION
We aimed at employing an experimental strategy
which would lead to particle infectivity and marker gene
transduction only when membrane fusion between indi-
vidual retroviral particles, resulting in mixing of their
respective lipid bilayers, occurred outside the cell. Since
HIV requires two cellular receptors for infectivity (CD4
and a specific coreceptor), we envisaged placing these
components on two separate particle preparations such
that infection of, and marker gene transduction to, the
appropriate HIV-Env-expressing target cell would be
possible only in the situation in which these components
became localized in close proximity in the same lipid
bilayer as a result of inter-retroviral fusion. The exact
strategy will be described in detail below and is illus-
trated in Fig. 2A.
Depending on the tropism to T-cells (T-tropic) or mac-
rophages (M-tropic), the respective HIV glycoprotein em-
ploys either CXCR-4 (T-tropic) or CCR-5 (M-tropic) as
specific coreceptor. Since the planned strategy requires
use of T- and M-tropic Env together with CXCR-4 and
CCR-5 coreceptor molecules, respectively, we analyzed
in an initial experiment whether inter-retroviral fusion
was specific for the correct combination of Env protein
and coreceptor molecule. HIV-like target and fusion par-
ticles were prepared as described previously (Sparacio
et al., 2000). Briefly, target particles were generated by
cotransfecting 293T cells with the Env-defective proviral
construct pNL4-3.Luc.R-E- (He et al., 1995) encoding the
luciferase gene instead of nef, plus expression vectors
for CD4 and either CXCR-4 or CCR-5. Fusion particles
were generated by cotransfecting pNL4-3Env3,
which is an Env-defective proviral construct with a dele-
tion in the packaging signal, plus expression vectors for
either T-tropic or M-tropic Env. Culture supernatants,
representing equal amounts of target and fusion parti-
cles, were mixed and preincubated for 90 min at 37°C to
allow potential fusion to occur. Subsequently, the mix-
tures were applied either to CD4/CXCR-4-expressing
293T cells or to Magi-CCR-5 cells (Chackerian et al.,
1997) and 2 to 3 days later, the luciferase activities in the
cell lysates were determined (see Fig. 1A). As expected
and as has been previously shown, target particles alone
did not lead to significant luciferase transduction (not
shown). However, mixtures of target and fusion particles
FIG. 1. Coreceptor specificity of HIV-Env-induced inter-retroviral fu-
sion. (A) Schematic depiction of strategy employed. Target particles
(left), generated as described under Materials and Methods, have
incorporated CD4 and either CXCR-4 (X4) or CCR-5 (R5) and encode
luciferase (luc). Fusion particles (middle), lacking luc, have incorpo-
rated either T- or M-tropic HIV-1 Env (T-Env or M-Env). Target particles,
fusion particles, or appropriate mixtures of target and fusion particles
were analyzed as to their ability to transmit luciferase (Luc) activity to
CD4-expressing cells coexpressing X4 or R5. For reasons of transduc-
tion efficiency, 293T cells stably expressing CD4 and CXCR-4 (Sparacio
et al., 2000) were employed for T-tropic Env-mediated transductions
and Magi-CCR-5 cells for M-tropic Env-mediated transductions. (B)
Luciferase gene transduction after inter-retroviral fusion. The glyco-
protein compositions of the respective mixed target and fusion parti-
cles are indicated and the resulting luciferase activities (total relative
light units (RLU) per culture given on the y axis) in transduced cell
lysates are given for a representative experiment (from three indepen-
dent experiments). The luciferase transduction value with the appro-
priate Env molecule in the fusion particles (i.e., matching the corecep-
tor molecule in the target particles) is taken as 100% and the transduc-
tion values, with the inappropriate Env molecule, are calculated as a
percentage of this.
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in which the incorporated coreceptor molecule in the
target particles was specific for the Env protein in the
fusion particle led to a large increase in transduced
luciferase activity, indicating that inter-retroviral fusion
had occurred (Fig. 1B). Controls, described previously
(Sparacio et al., 2000), confirmed that these positive
transduction values were absolutely dependent on the
presence and functionality of all the HIV-Env, CD4, and
coreceptor components. In contrast, if the coreceptor
molecule on the target particle was not appropriate for
the HIV-Env protein incorporated into the fusion particle,
mixing these two particle populations did not result in
significant luciferase transduction (Fig. 1B).
The strategy which we have developed to analyze
whether inter-retroviral fusion can occur outside the cell
is illustrated in Fig. 2A. In this strategy, target particles,
encoding luciferase, have incorporated M-tropic Env and
CXCR-4. Fusion particles have incorporated CD4 and
CCR-5. The Cl–4 target cells employed are stably trans-
fected CV-1 cells expressing T-tropic Env (Krausslich et
al., 1993). Thus, in contrast to other strategies (e.g., Fig.
1), neither the target particles nor the fusion particles are
able to fuse with the target Cl–4 cells. Fusion between
target and fusion particles, mediated by M-tropic Env and
CD4/CCR5, can, however, potentially occur and, in the
situation in which the respective lipid bilayers truly mix,
this should result in colocalization of CD4 from the fusion
particle and CXCR-4 from the target particle in the same
membrane. Thereafter, the resultant fused viral structure
should potentially be able to infect and transduce lucif-
erase activity to Cl–4 cells. In fact, as shown in Fig. 2B,
this is the case and significant luciferase activity was
detectable. Transduction with target particles alone or
with mixtures of M-Env/X4 target particles and fusion
particles lacking either CCR-5 or CD4 resulted in only
low luciferase transduction (Fig. 2B). The control of
mixed particle preparations, in which the fusion particles
lacked CCR-5 but had still incorporated CD4, was very
important. We had considered the possibility that CD4 on
the fusion particle could bind to, and induce conforma-
tional changes in, the T-tropic Env on the cell surface.
This would perhaps then allow binding of CXCR-4-con-
taining target particles and fusion of these with the Cl–4
cells in a manner similar to the trans-receptor mecha-
nism for infection described by others (Speck et al.,
1999). However, the fact that the luciferase values from
this control are in the same range as in the complete
absence of fusion particles shows that infection by a
putative trans-receptor mechanism does not occur here.
Thus, the positive transduction values obtained on ap-
plication of mixtures of target particles with incorporated
M-tropic Env and CXCR-4 and fusion particles with in-
corporated CD4 and CCR-5 strongly point to membrane
fusion between retroviral particles occurring without in-
volvement of the cell.
It has been known for some time that cells in general,
and in particular cells overexpressing certain surface
glycoproteins, can release membrane vesicles into the
medium. We thus considered the possibility that mem-
brane vesicles, with incorporated surface glycoprotein,
could be contaminants in preparations of fusion parti-
cles. These membrane vesicles would also be able to
fuse with target particles and the resultant fused struc-
tures would now also be able to transduce luciferase
activity to target cells. In order to control for this possi-
bility, M-Env/X4 target particles were mixed and incu-
bated with the culture supernatants of cells overexpress-
ing CD4 and CCR-5, but not producing HIV-like particles.
Transfer of this mixture to Cl–4 target cells resulted in
FIG. 2. Inter-retroviral fusion independent of the target cell. (A)
Schematic depiction of strategy employed. Target particles (left), gen-
erated as described under Materials and Methods, have incorporated
M-tropic Env and CXCR-4 (X4) and encode luciferase (luc). Fusion
particles (middle), lacking luc, have incorporated CD4 and CCR-5 (R5).
Target particles, fusion particles, or appropriate mixtures of target and
fusion particles were analyzed as to their ability to transmit luciferase
(Luc) activity to Cl–4 cells expressing T-tropic Env. (B) Luciferase gene
transduction after inter-retroviral fusion. The glycoprotein compositions
of the respective target and fusion particles are indicated and the
resulting luciferase activities (total relative light units (RLU) per culture
given on the y axis) in transduced cell lysates are given for a repre-
sentative experiment (from three independent experiments). The lucif-
erase transduction value obtained with mixtures of the potentially
fusable M-Env/X4 target particles plus CD4/R5 fusion particles is taken
as 100% and the transduction values for the further controls are calcu-
lated as a percentage of this.
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only a low level of luciferase transduction (Fig. 2B), mak-
ing it unlikely that CD4/CCR-5-containing membrane ves-
icles were significantly contributing to the luciferase
transduction obtained on mixing target and fusion parti-
cles. Further control experiments concerning the possi-
ble contribution of membrane vesicles were also repeat-
edly performed employing the experimental strategy il-
lustrated in Fig. 1A. In these cases, culture supernatants
from cells expressing HIV-Env, but not releasing parti-
cles, were mixed with target particles with incorporated
CD4 and the appropriate coreceptor. The levels of lucif-
erase transduction obtained on transfer of these mix-
tures to CD4/coreceptor-expressing target cells were in
general low (about 1–2%) although, occasionally, values
in the range of 20% of that achieved with mixtures of
target and fusion particles were obtained (data not
shown). Thus, these control experiments indicate that
the bulk of the luciferase transduction on mixing target
and fusion particles can be attributed to genuine inter-
retroviral fusion.
We next aimed at extending our analysis of inter-
retroviral fusion to include other fusion-mediating mole-
cules and have chosen MuLV-Env and its cellular recep-
tor PiT-2 (see Fig. 4A). 293T cells are infectible with HIV
vector particles, pseudotyped with amphotropic MuLV-
Env, and thus should express PiT-2. However, as shown
in Fig. 3A (left), the endogenous PiT-2 expression level is
very low and cannot be detected in indirect immunoflu-
FIG. 3. Expression of PiT-2 and MuLV-Env and incorporation into HIV-like particles. (A) Indirect immunofluorescence with anti-PiT-2 serum of
untransfected 293T cells (left) and 293T cells transfected with PiT-2 expression plasmid (right). (B) Western blot analyses employing anti-PiT-2 serum
of cell lysates (cells) and enriched HIV-like particles (virus) from 293T cells expressing PiT-2 with () or without () coexpression of HIV-like particles
(gag) as indicated. (C) Western blot analyses, employing anti-HIV p24 antibodies, of cell lysates (cells) and enriched HIV-like particles (virus) from 293T
cells coexpressing HIV-like particles and MuLV-Env and cultivated in the presence () or absence () of Saquinavir as indicated. (D) Western blot
analyses of enriched HIV-like particles from cells expressing MuLV-Env alone (lane 3) or coexpressing HIV-like particles (lanes 1, 2) and cultivated
in the presence () or absence () of Saquinavir as indicated.
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orescence with specific anti-PiT-2 serum. Thus, for the
production of PiT-2-containing target particles, 293T cells
were cotransfected with pNL4-3.Luc.R-E- and an expres-
sion vector for PiT-2. Transfected cells now exhibited
bright PiT-2-specific immunofluorescence (Fig. 3A, right).
Western blot analyses employing anti-PiT-2-specific se-
rum revealed several bands with diverse mobilities in the
high-molecular-weight range, including species in the
range of 70 kDa, only in the lysates of cells transfected
with PiT-2 expression plasmid. It has previously been
demonstrated that, as a result of its numerous mem-
brane-spanning domains, the 71-kDa PiT-2 protein forms
aggregates in detergent solution (Chien et al., 1997).
Thus, the PiT-2-related species with low electrophoretic
mobilities observed in Fig. 3B presumably represent
PiT-2 aggregates. This is despite incubation of the ly-
sates in SDS sample buffer for polyacrylamide gel elec-
trophoresis (PAGE) only at 25°C, a treatment described
to counteract aggregation (Chien et al., 1997). PiT-2-
related species could also be clearly detected in lysates
of HIV-like target particles, enriched by centrifugation
through a cushion of sucrose (Fig. 3B), but was virtually
absent from pellets obtained on centrifugation of me-
dium from transfected cells expressing PiT-2 alone and
not releasing HIV-like particles. These results confirm
that incorporation of PiT-2 into target particles has oc-
curred. Fusion particles were generated by cotransfec-
tion of 293T cells with pNL4-3Env3 and an expres-
sion vector for amphotropic MuLV-Env and treatment
with or without 1.5 M HIV-1 protease inhibitor, Saquina-
vir (see Fig. 4A). As shown in Fig. 3C, the treatment with
Saquinavir completely inhibited HIV-1 protease and only
uncleaved Pr55gag, and not p24, could be observed in
lysates of transfected cells and released fusion particles
in the medium. This means that the HIV-1 protease-
mediated removal of the MuLV-R-peptide should also be
completely inhibited. Both mature and immature HIV-like
particles incorporated equal amounts of MuLV-Env (as
illustrated by Western blot for gp71) (Fig. 3D) into re-
leased fusion particles.
As shown in Fig. 4B, application of PiT-2-containing
target particles to 293T cells did not result in measurable
luciferase transduction. However, when mixtures of PiT-
2-containing target particles and MuLV-Env-containing
fusion particles were preincubated and then applied to
293T cells, the luciferase transduction levels increased
dramatically. This occurred only when target particles
were generated in cells cotransfected with PiT-2 expres-
sion vector, indicating that the endogenous expression
of PiT-2 in 293T cells is not sufficient for its functional
incorporation into particles. Furthermore, luciferase
transduction, indicative of inter-retroviral fusion, was ap-
parent only in the case in which mature MuLV-Env-
containing fusion particles, in which the MuLV-Env R-
peptide will have been removed by the HIV protease,
were employed. Mixtures of PiT-2-containing target par-
ticles and immature MuLV-Env-containing fusion parti-
cles, i.e., produced in the presence of Saquinavir, did not
FIG. 4. Inter-retroviral fusion mediated by fusion-competent MuLV-Env and PiT-2. (A) Schematic depiction of strategy employed. Target particles
encoding luciferase (luc) (left), generated as described under Materials and Methods, have been produced in normal 293T cells (no PiT-2) or in 293T
cells additionally overexpressing PiT-2 (PiT-2). Fusion particles (middle) lacking luc, produced in untreated cells (mature) or in cells treated with the
HIV protease inhibitor Saquinavir (immature), have incorporated amphotropic MuLV-Env. Target particles, fusion particles, or appropriate mixtures of
target and fusion particles were analyzed as to their ability to transmit luciferase (Luc) activity to 293T cells. (B) Luciferase gene transduction after
inter-retroviral fusion. The glycoprotein compositions of the respective target and fusion particles and the maturation status of the fusion particles are
indicated. The resulting luciferase activities (total relative light units (RLU) per culture given on the y axis) in transduced cell lysates are given for a
representative experiment (from three independent experiments). The luciferase transduction value obtained with a mixture of PiT-2-containing target
particles with mature MuLV-Env-containing fusion particles is taken as 100% and the transduction values for the further controls are calculated as
a percentage of this.
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result in measurable luciferase transduction at all. This
was not due to an effect of protease inhibitor on lucif-
erase transduction per se since addition of Saquinavir to
infectious target particles, e.g., HIV-Env-target particles
added to CD4/CXCR-4 293T cells, did not affect the
extent of luciferase transduction. The effect is also not
due to inter-retroviral fusion per se being inhibited as a
result of the fusion particle being immature. Thus, in
separate experiments, employing the strategy illustrated
in Fig. 1, inter-retroviral fusion between CD4/CXCR-4-
containing target particles and immature HIV-Env-con-
taining fusion particles (generated either by treatment
with Saquinavir or by employing an expression construct
encoding inactive protease) was examined. Although the
extent of transduction was reduced in comparison to that
observed using mature fusion particles, it was clearly
detectable (not shown). In line with this, Zhou and Aiken
(2001) observed that fusion particles which were imma-
ture as a result of a mutation at the cleavage site be-
tween CA and NC could still efficiently engage in inter-
retroviral fusion. We thus interpret the complete lack of
inter-retroviral fusion with immature particles with incor-
porated MuLV-Env to be due to lack of processing of the
MuLV-Env R-peptide. On the other hand, since (in sam-
ples not treated with Saquinavir) protease-induced acti-
vation of MuLV-Env to fusion competence occurs only
during or after budding of virions, it is unlikely that puta-
tively contaminating cellular membrane vesicles will con-
tain fusion-competent MuLV-Env which could signifi-
cantly contribute to the increase in luciferase transduc-
tion observed on inter-retroviral fusion.
The results presented in this article confirm, and sub-
stantially extend, our previously published data which
described inter-retroviral fusion for the first time. We
show that inter-retroviral fusion occurs in suspension
independent of phenomena involving the target cell.
Zhou and Aiken (2001) recently confirmed our original
observation that inter-retroviral fusion can occur. In that
report, it was demonstrated that reagents inhibiting HIV-
Env binding, added subsequent to mixing and incubation
of particle preparations, did not significantly reduce in-
fectivity of fused viral structures (mediated by an addi-
tionally coincorporated ecotropic MuLV-Env). Although
this indicates that interactions between the respective
target and fusion particles occur in the culture superna-
tant, it does not rigorously show that inter-retroviral fu-
sion goes to completion outside the cell. This is the case
with the strategy employed here (Fig. 2).
We have additionally demonstrated here that inter-
retroviral fusion can also be mediated by MuLV-Env and
PiT-2. Incorporation of PiT-2, which has a membrane
topology exhibiting several (in fact as recently demon-
strated (Salaun et al., 2001), 12) membrane-spanning
domains, into HIV-like particles was readily demonstrat-
able. Although MuLV-Env was incorporated equally into
mature and immature particles, inter-retroviral fusion
was observed only with mature particles containing ac-
tive HIV protease capable of removing the R-peptide
from the C-terminus of MuLV-Env. These observations
demonstrating MuLV-Env/PiT-2-mediated inter-retroviral
fusion are presumably extendable to many other viral
glycoproteins and their respective cellular receptor mol-
ecules. Thus the phenomenon of inter-retroviral fusion
may have far-reaching consequences in nature as we
have previously discussed (Sparacio et al., 2000). Further
use of assays involving inter-retroviral fusion may be
helpful in elucidating details of processes contributing to
viral glycoprotein function and viral infectivity (e.g., Zhou
and Aiken, 2001). Additionally as discussed previously
(Sparacio et al., 2000), it may be possible to optimize the
process of HIV-Env-mediated inter-retroviral fusion and
enrich for conformational HIV-Env epitopes of relevance
for vaccination strategies.
MATERIALS AND METHODS
Constructs and cell lines employed
pNL4-3.Luc.R-E- (He et al., 1995), pNL4-3Env3,
encoding target and fusion particles, respectively, pSG5-
CD4-GPI, encoding GPI-anchored CD4, pFusin (Deng et
al., 1996), encoding CXCR-4, and pLAcEnv/neo, encod-
ing wild-type HIV-Env, have been described previously
(Sparacio et al., 2000). pCCR-5 (Deng et al., 1996) has
been employed here to express CCR-5. pGRE-Menv is an
expression plasmid for M-tropic HIV-Env. It is a modified
version of our previously described dexamethasone-in-
ducible plasmid, plGRE-env (Kruger et al., 1996), in which
a KpnI–BsmI fragment (pNL4-3 nucleotides 6343–8044)
has been exchanged for the same fragment from the
M-tropic AD8 sequence (Freed et al., 1995). We thank the
staff of the laboratory of K. Conzelmann, Munich, Ger-
many, for performing this cloning step. pHIT436 encodes
amphotropic MuLV Env (Soneoka et al., 1995), and
pCRAV, a kind gift from J. M. Heard (Rodrigues and
Heard, 1999), encodes a tagged form of PiT-2, a phos-
phate transporter protein which is the cellular receptor
for amphotropic MuLV-Env.
Generation of target and fusion particles and
transductions
Target and fusion particles were generated and inter-
retroviral fusion was analyzed as previously described
(Sparacio et al., 2000). Briefly, target particles were gen-
erated by transfection of pNL4-3.Luc.R-E- plus the re-
quired glycoprotein expression vector(s) and fusion par-
ticles by transfection of pNL4-3Env3 and the re-
quired glycoprotein expression vector(s) into 293T cells.
In order to achieve optimal expression from pGRE-Menv,
25 nM dexamethasone was added to the medium of
transfected cells. In some experiments, Saquinavir (Hoff-
mann–La Roche, Basel, Switzerland) was added to the
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medium of transfected cells at a concentration of 1.5 M.
The amounts of released particles were quantitated by
ELISA for HIV-1-CA (Innogenetics, Ghent, Belgium). Pro-
tein expression was confirmed by indirect immunofluo-
rescence as described previously (Sparacio et al., 2000),
here additionally employing the supernatant of hybrid-
oma 183-H12-5C cells (Chesebro et al., 1992), which
release mouse monoclonal antibody reactive with HIV-1
p24, goat anti-MuLV-Env (a kind gift from R. Friedrich,
University of Giessen, Germany), and rabbit anti-PiT-2
(a kind gift from D. Kabat, Oregon Health Sciences Uni-
versity, Portland) as required. HIV-like particles in culture
supernatants were concentrated by centrifugation
through a cushion of sucrose (Krausslich et al., 1993) and
Gag, MuLV-Env, and PiT-2 proteins were analyzed by
PAGE and Western blot analyses using standard proce-
dures. Importantly, as had previously been demonstrated
to be of importance (Chien et al., 1997), samples con-
taining PiT-2 were incubated in loading buffer for PAGE
only at 25°C. Filtered cell supernatants containing target
and fusion particles were mixed (at a particle ratio of 1:1)
in the presence of 8 M polybrene and subsequently
applied to fresh target cells. Depending on the experi-
ment, target cells were untransfected 293T cells, 293T
cells stably expressing CD4 and CXCR-4 (Sparacio et al.,
2000), Magi-CCR-5 cells (Chackerian et al., 1997), or
T-tropic Env expressing Cl–4 cells (Krausslich et al.,
1993). Two or 3 days later, lysates of transduced cells
were prepared and total luciferase activity per culture
was measured using standard procedures.
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